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Abstract
Background: Human papillomavirus-positive oropharyngeal squamous cell carcinoma is increasing in incidence
worldwide. Current treatments are associated with high survival rates but often result in significant long-term
toxicities. In particular, long-term dysphagia has a negative impact on patient quality of life and health. The aim
of PATHOS is to determine whether reducing the intensity of adjuvant treatment after minimally invasive transoral
surgery in this favourable prognosis disease will result in better long-term swallowing function whilst maintaining
excellent disease-specific survival outcomes.
Methods/Design: The study is a multicentre phase II/III randomised controlled trial for patients with biopsy-proven
Human papillomavirus-positive oropharyngeal squamous cell cancer staged T1-T3 N0-N2b with a primary tumour
that is resectable via a transoral approach. Following transoral surgery and neck dissection, patients are allocated
into three groups based on pathological risk factors for recurrence. Patients in the low-risk pathology group will
receive no adjuvant treatment, as in standard practice. Patients in the intermediate-risk pathology group will be
randomised to receive either standard dose post-operative radiotherapy (control) or reduced dose radiotherapy.
Patients in the high-risk pathology group will be randomised to receive either post-operative chemoradiotherapy
(control) or radiotherapy alone. The primary outcome of the phase II study is patient reported swallowing function
measured using the MD Anderson Dysphagia Inventory score at 12 months post-treatment. If the phase II study is
successful, PATHOS will proceed to a phase III non-inferiority trial with overall survival as the primary endpoint.
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Discussion: PATHOS is a prospective, randomised trial for Human papillomavirus-positive oropharyngeal cancer,
which represents a different disease entity compared with other head and neck cancers. The trial aims to
demonstrate that long-term dysphagia can be lessened by reducing the intensity of adjuvant treatment without
having a negative impact on clinical outcome. The study will standardise transoral surgery and post-operative
intensity-modulated radiotherapy protocols in the UK and develop a gold-standard swallowing assessment panel.
An associated planned translational research programme, underpinned by tumour specimens and sequential blood
collected as part of PATHOS, will facilitate further empirical understanding of this new disease and its response to
treatment.
Trial registration: This study is registered with ClinicalTrials.gov identifier NCT02215265.
Background
Oropharyngeal squamous cell carcinoma (OPSCC) is a
rapidly increasing disease in the UK and other developed
countries as a result of Human papillomavirus (HPV)
genotype 16 infection. Currently, over 70 % of OPSCC
in Europe is HPV 16 positive [1]. HPV status is a strong
and independent prognostic factor for survival, and
HPV-positive OPSCC has a 58 % reduction in the risk of
death compared to HPV-negative OPSCC [2]. Other
factors known to influence prognosis in HPV-positive
OPSCC include smoking, particularly current smoking,
nodal stage and patient comorbidities [2–4].
Currently, the management of OPSCC is based on the
stage of disease as well as clinician and patient prefer-
ence, irrespective of HPV status. Early stage disease is
treated with either surgery or radiotherapy (RT) alone,
whilst locally advanced disease requires multimodality
treatment with primary chemoradiotherapy (CRT) +/-
neck dissection or primary surgical resection followed by
post-operative RT/CRT. Severe late toxicities after multi-
modality treatment are reported in up to 43 % of pa-
tients and may be permanent [5]. Patients and their
carers report dysphagia to be a primary cause for dis-
tress, and patient reported dysphagia independently pre-
dicts for poor long-term quality of life (QOL) [6, 7].
Patients with HPV-positive OPSCC tend to be young
(mean age 54 years) and fit at presentation [2]. Reducing
the adverse impact of treatment on function and main-
taining good QOL are therefore of paramount import-
ance in these patients who have good prognosis disease.
Role of transoral surgery
With the advent of minimally invasive techniques, such
as Transoral Laser Microsurgery (TLM) and Transoral
Robotic Surgery (TORS), there has been renewed inter-
est in primary surgical treatment for OPSCC as these
techniques result in less morbidity when compared to
open surgery. There are as yet no prospective rando-
mised data on TLM/TORS for OPSCC but retrospective
studies have demonstrated excellent outcomes. A US
study of 204 patients with stage III-IV OPSCC treated
with TLM and neck dissection found rates of local con-
trol (LC), overall survival (OS) and disease-free survival
(DFS) to be 97, 86 and 82 % respectively at 3 years, with
HPV-positive OPSCC having even better outcomes [8].
Most patients had adjuvant treatment (RT/CRT), which
increased toxicity. Single centre data on TLM in the UK
is also encouraging. Data from Liverpool on 153 patients
with T1-T3 OPSCC (66 % HPV positive) treated with
TLM and neck dissection demonstrate 3 year OS of
84.5 %, disease specific survival (DSS) of 91.7 % and DFS
of 78.2 %. Patients with HPV-positive OPSCC had a
71 % reduction in the risk of death. 83.6 % of patients
received adjuvant treatment. (TMJ, manuscript submit-
ted). Single institution data also show a functional ad-
vantage with upfront transoral surgery compared to
primary CRT [9]. A UK study compared swallowing
function between 23 patients with locally advanced
OPSCC treated with TLM +/- adjuvant therapy and 33
matched patients treated with CRT from a historical
cohort and reported improved early swallowing function
at 3 months in the upfront surgery group, using 3 differ-
ent swallowing measures, including the MD Anderson
Dysphagia Inventory (MDADI) score [10].
Adjuvant therapy: risk factors, RT dose and use of
chemotherapy
Currently, decisions about adjuvant therapy after surgery
are based on the presence of pathological risk factors
established more than 20 years ago in studies that in-
cluded squamous cancers from multiple head and neck
anatomical subsites and that did not test for tumour
HPV status [11]. These risk factors include surgical mar-
gin status, presence of perineural and vascular invasion,
number of lymph node metastases and presence of
extracapsular spread (ECS) of nodal disease. The rele-
vance of these risk factors in HPV-positive disease has
been questioned and the optimum adjuvant treatment
protocols for HPV-positive OPSCC are yet to be deter-
mined [12].
Adjuvant RT after surgery for advanced head and neck
cancers improved LC in the RTOG 73-03 trial [13].
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Subsequent studies recommended a minimum dose of
57.6Gy to the primary site and involved nodal areas and
doses of up to 63Gy to areas of ECS [14]. However,
lower doses of adjuvant RT may be sufficient for HPV-
positive OPSCC based on the following: (i) observations
that HPV-positive cell lines show increased radiosensitiv-
ity compared to HPV-negative cell lines in vitro [15, 16];
(ii) phase II data (ECOG 1308) showing equivalent LC
rates at 2 years with reduced dose RT (54Gy in 27 × 2Gy
fractions) in patients with HPV-positive OPSCC who
achieved a complete response after 3 cycles of in-
duction chemotherapy [17]; (iii) use of lower doses of
prophylactic RT (50Gy in 35 × 1.4Gy fractions, equiva-
lent to 43Gy in 2Gy fractions) with no increase in
recurrences [18].
The EORTC 22931 and RTOG 9501 Randomised
Controlled Trials (RCTs) showed that adjuvant CRT
improved LC and DFS compared with adjuvant RT alone
in some patients with advanced head and neck cancer
[19, 20]. When the results of both studies were pooled,
adjuvant CRT significantly improved OS in patients with
positive (or ‘involved’) surgical margins and/or presence
of nodal ECS [21]. These pathological features are now
widely used criteria for adjuvant CRT. There is variation
in practice however, particularly around the issue of sur-
gical margins with positive (<1 mm) and close (1-5 mm)
margins being grouped together in some studies. A sur-
vey of clinical oncologists from 17 UK centres reported
that all would recommend adjuvant CRT for positive
surgical margins (<1 mm) whilst only 30 % would advo-
cate its use for close margins (1–5 mm) and 88 % for
ECS [22]. The relevance of the EORTC 22931 and
RTOG 9501 study results should be questioned in the
context of HPV-positive OPSCC. Patients in these stud-
ies had tumours from multiple head and neck anatom-
ical subsites and the prevalence rate of HPV-positive
OPSCC would have been significantly lower than the
current rate [1]. Evidence for using adjuvant CRT after
transoral surgery for OPSCC is also lacking. A retro-
spective study of TLM for advanced OPSCC showed
that the addition of chemotherapy to adjuvant RT did
not improve outcomes even in the presence of ECS, pos-
sibly because a high proportion of patients in that study
had HPV-positive tumours with already excellent out-
comes [8, 12].
Dysphagia after treatment
There are several factors that may contribute to dyspha-
gia after treatment. Dysphagia after RT has been shown
to correlate with increased mean doses of radiation to
swallowing-related organs, with a higher mean dose to
superior pharyngeal constrictor muscle region and lar-
ynx being particularly associated with worse long-term
swallowing outcomes [23, 24]. The sigmoidal shape of
the normal tissue complication probability curve indi-
cates that increasing mean dose to pharyngeal muscula-
ture between 50Gy and 60Gy is a critical point at which
risk of long-term dysphagia begins to inflect upwards,
suggesting that reducing radiation dose from 60Gy to
50Gy could impart a clinically significant improvement
in long-term swallowing outcomes [23]. Adding concur-
rent chemotherapy to primary or adjuvant RT increases
the risk of dysphagia: a systematic review of TORS for
OPSCC showed clear demarcation in swallowing out-
comes across a variety of outcome measures in patients
who received adjuvant RT alone compared to adjuvant
CRT [25].
Study rationale
Current treatments for HPV-positive OPSCC are
associated with high survival rates but often result in sig-
nificant long-term toxicities, particularly affecting swal-
lowing function, that have a negative effect on QOL.
Patients recruited into PATHOS will undergo transoral
surgery to resect their primary tumours as well as a neck
dissection. Post-operatively, they will be stratified into
risk groups according to the presence or absence of
pathological risk factors for recurrence. The aim of
PATHOS is to determine whether reducing the intensity
of adjuvant treatment after minimally invasive surgery
in HPV-positive OPSCC, either by lowering RT dose in
intermediate-risk patients or omitting chemotherapy in
high-risk patients will result in better swallowing func-
tion, whilst maintaining excellent clinical outcomes. The
primary outcome of the PATHOS phase II study will be
long-term patient reported swallowing function mea-
sured using the MDADI score at 12 months post-
treatment. Secondary outcomes will include local control
rates and survival as well as a panel of objective and
self-reported swallowing assessments. If the phase II
study is successful, PATHOS will continue to a phase III
study. The primary outcome of the proposed phase III
study will be overall survival.
Methods/Design
Study design
PATHOS is a multicentre, open label, parallel group
phase II/III RCT funded by Cancer Research UK
(CRUK). Patients must have biopsy proven OPSCC and
should be clinically staged T1–T3 N0-N2b M0. Their
primary tumour must be considered resectable via a
transoral approach as determined by the local Multidis-
ciplinary Team (MDT). HPV-positivity will be confirmed
by central testing of diagnostic biopsy specimens by p16
immunohistochemistry and high risk HPV in-situ hy-
bridisation. Synchronous neck dissection will be under-
taken as per standard protocols depending upon the
volume of regional metastatic disease. Following surgery,
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patients will be allocated into study groups based on
histological findings (Fig. 1):
Group A: Patients whose tumours have no adverse
histological features will not receive any adjuvant treat-
ment as per standard of care.
Group B: Patients with T3 tumours (or T1–T2 tu-
mours with additional risk factors), N2a (metastasis in
single ipsilateral node 31–60 mm diameter) or N2b (me-
tastasis in multiple ipsilateral nodes <61 mm diameter),
tumours with evidence of perineural and/or vascular in-
vasion, or close margins (1–5 mm) around the primary
tumour specimen but with negative marginal biopsies
and no evidence of cervical lymph node ECS. Patients in
this group will be randomised to either post-operative
RT 60Gy in 30 fractions over 6 weeks (Control Arm B1)
or post-operative RT 50Gy in 25 fractions over 5 weeks
(Test Arm B2).
Group C: Patients with tumours of any T or any N
stage with the following high risk pathological features:
positive (<1 mm) margins around the primary tumour
(but with negative marginal biopsies) and/or evidence of
cervical lymph node ECS. Patients in this group will be
randomised to either post-operative CRT 60Gy in 30
fractions over 6 weeks with concurrent cisplatin (Con-
trol Arm C1) or post-operative RT 60Gy in 30 fractions
over 6 weeks without chemotherapy (Test Arm C2).
Fig. 1 Trial schema
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Participating sites
The phase II trial will recruit at over approximately 20
sites in the UK. Participating sites will be required to
complete a registration form to confirm that they have
adequate resources and experience to conduct the trial.
The planned phase III trial will recruit across Europe.
Participant eligibility
Participants are eligible to enter the trial pre-operatively
if they meet all of the inclusion criteria and none of the
exclusion criteria (Table 1). Post-operatively, patients al-
located to Groups B and C on the basis of their path-
ology must re-confirm their consent for the study and
will be assessed for their suitability for adjuvant treat-
ment. Patients in Group B must be fit to undergo RT.
Patients in Group C must be fit to undergo CRT and
meet additional criteria as per Table 2.
Method of randomisation
Patients in Groups B and C will be randomised to a trial
arm using the method of minimisation with a random
element. Randomisation will be performed centrally by
the Wales Cancer Trials Unit (WCTU). Participants will
be stratified prior to randomisation by T stage, N stage,
smoking history and treating centre.
Study Interventions
Surgery
Surgery to the primary site will be carried out by TLM
or TORS, while a standard open approach will be used
for neck dissection. These can be carried out as a single
or staged procedure. Surgery should take place within
4 weeks (maximum 6 weeks) of study registration.
Transoral Laser Microsurgery (TLM) and marginal
biopsies TLM will be conducted according to the prin-
ciples outlined by Steiner and Ambrosch [26]. Tumours
will be removed in several (at least two) planned pieces
following trans-tumoural resection. It is mandatory that
representative marginal biopsies are taken from the
tumour bed in all cases of TLM to ensure complete sur-
gical removal of the tumour. Re-resection is allowed
when initial marginal biopsies are found to be positive
for microscopic disease. If positive marginal biopsies are
obtained on re-resection, the patient is withdrawn from
the trial.
Transoral Robotic Surgery (TORS) TORS involves
en bloc removal of the tumour as per the principles out-
lined in the da Vinci Transoral Surgery Procedure
Guide:
http://www.uphs.upenn.edu/pennorl/education/documents/
daVinciTORSProcedureGuide.pdf. As tumours are typ-
ically removed en bloc, marginal biopsies are usually not
required.
Neck Dissection Patients with clinically node negative
(cN0) disease will undergo a selective neck dissection
involving clearance of at least nodal levels II and III.
Table 1 Inclusion and exclusion criteria for all patients in
PATHOS trial
Inclusion criteria for all patients
1. Histologically confirmed diagnosis of OPSCC
2. HPV-positive on central testing
3. Stage T1-T3, N0-N2b tumours (based on cross-sectional imaging in-
vestigations carried out within 6 weeks of study entry)
4. Local MDT decision to treat with primary transoral resection and
neck dissection
5. Fit for surgery and adjuvant treatment as assessed by the local MDT
6. Aged 18 or over
7. Able to provide written informed consent
Exclusion criteria for all patients
1. HPV-negative tumours
2. Stage T4 tumours and/or T1–T3 tumours where transoral surgery is
considered not feasible
3. N2c–N3 nodal disease
4. Unresectable retropharyngeal node involvement
5. Current smokers with N2b disease including smokers up to 2 years
before diagnosis
6. Any pre-existing medical condition likely to impair swallowing func-
tion and/or a history of pre-existing swallowing dysfunction prior to
index oropharyngeal cancer
7. Patients with distant metastatic disease (stage IVc)
8. Patients with a history of malignancy in the last 5 years, except basal
cell carcinoma of the skin or carcinoma in-situ of the cervix
9. Women who are pregnant or breastfeeding and fertile women who
will not be using contraception during the trial
Table 2 Additional inclusion and exclusion criteria for patients
in Group C
Inclusion criteria for patients in Group C
1. Bone marrow reserve adequate for chemotherapy (i.e. absolute
neutrophil count (ANC) ≥ 1.5 × 109/l and platelet count ≥
100 × 109/l)
2. Adequate creatinine clearance defined as GFR≥ 50 ml/min
Exclusion criteria for patients in Group C
1. History of significant cardiac or other medical conditions that
preclude the use of cisplatin and intravenous hydration
2. Clinically significant hearing impairment sufficient to affect daily
living and/or pre-existing tinnitus
3. Pre-existing peripheral neuropathy that precludes the use of cisplatin
4. Hypersensitivity to the active substance or other platinum
compounds or to any of the other excipients
5. Dehydrated condition
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Patients with clinically node positive (cN+) disease will
undergo clearance of lymph node levels II and III and
any additional involved lymph node levels. Patients with
neck disease involving adjacent structures will undergo a
modified radical neck dissection. In the case of non-
lateralised primary tumours, as an alternative to non-
surgical treatment (see below), some centres may under-
take a selective neck dissection of the contralateral cN0
neck.
Radiotherapy
Patients should start RT within 5 weeks and no later
than 6 weeks from surgery, so that combined treatment
(surgery and RT) is completed within 11 weeks to avoid
poor LC and survival rates that result from protracted
treatment [11]. Patients are managed as category 1 as
per the Royal College of Radiologists Guidelines and RT
should be completed within 6 weeks for patients having
60Gy in 30 fractions and within 5 weeks for those having
50Gy in 25 fractions [27].
The primary tumour should be categorised as latera-
lised or non-lateralised based on clinical and radiological
assessments.
 Lateralised tumour: Tonsillar tumour confined to
the tonsillar fossa or extending onto or into the
adjacent base of tongue and/or soft palate by less
than 1 cm.
 Non-lateralised tumour: Tonsillar tumour that
involves the adjacent base of tongue and/or soft
palate by more than 1 cm or a tumour that arises
from a midline structure (base of tongue, soft palate,
posterior pharyngeal wall).
Patients with lateralised tumours should undergo uni-
lateral neck RT, regardless of the nodal stage of the ipsi-
lateral neck. Patients with non-lateralised tumours
should undergo bilateral neck RT, except in cases where
they have undergone contralateral selective neck dissec-
tion and pN0 status is confirmed on that side (see
above).
PATHOS uses a geometric approach to define target
volumes. Pre-operative imaging, pan-endoscopy reports,
operative findings and pathology information should be
used to delineate target volumes. The Clinical Target
Volume 1 (CTV1) includes the primary and nodal
tumour beds with a margin (1–1.5 cm) and all patho-
logically involved nodal levels. Arms B1, C1, C2 receive
60Gy/30 fractions and Arm B2 receives 50Gy/25 frac-
tions. The Clinical Target Volume 2 (CTV2) includes all
at risk uninvolved nodal levels that require prophylactic
RT. Arms B1, C1, C2 receive 54Gy/30 fractions and
Arm B2 receives 50Gy/25fractions. Some centres may, a
priori opt to boost high-risk sub-volume(s) for patients
in Group C to 66Gy/30 fractions. Neck node levels for
prophylactic RT should be outlined according to updated
consensus guidelines and atlas [28]. A margin (3–5 mm)
will be added to each CTV to produce the respective
Planning Target Volume.
Dose constraints to the following organs at risk will be
used for treatment plan optimisation: spinal cord, brain-
stem, parotid glands. Investigators are also encouraged
to contour swallowing-related structures. These include
the pharyngeal constrictor muscles (superior, middle and
inferior), supraglottic/glottic larynx, cricopharyngeus,
oesophageal inlet, cervical oesophagus and oral cavity
and should be outlined according to the PATHOS atlas
of swallowing structures, itself based on previously pub-
lished guidelines [24, 29]. The swallowing structures will
not be used for treatment plan optimisation but swal-
lowing outcomes will be correlated to the dose received
by these structures. All patients will be planned using
Intensity Modulated Radiotherapy (IMRT).
Chemotherapy
The following regimens can be used: Cisplatin 100 mg/m2
administered intravenously in a three weekly-cycle on days
1 and 22 of the RT schedule or Cisplatin 40 mg/m2 weekly
for a maximum of 6 weeks. Carboplatin may be used in-
stead of Cisplatin from cycle 2 onwards if the patient de-
velops complications (ototoxicity, impaired renal function)
related to Cisplatin.
Assessments and outcomes
Comprehensive assessment of swallowing function re-
quires a multidimensional panel of measures that incor-
porates instrumental examination of swallowing along
with clinician-rated and patient reported outcomes. A
functional outcomes panel for assessing swallowing
function has been developed for PATHOS (Table 3). The
following assessments will be conducted prior to sur-
gery, 4 weeks post surgery and at 4 weeks, 6, 12 and
24 months post treatment: (1) MD Anderson Dysphagia
Inventory score (MDADI); (2) Water swallow test
(WST); (3) Performance Status Scale-Head and Neck
(PSS-HN); (4) Quality of Life questionnaires (EORTC
QLQ-C30 and EORTC QLQ-H&N35). Patients will also
undergo a videofluoroscopy (VF) assessment prior to
surgery, at 4 weeks post surgery and at 12 months post
treatment. CTCAE Toxicity (v4.03) will be assessed
weekly during and at the end of RT and at 4 weeks, 6, 12
and 24 months.
Primary outcome measures
The primary outcome of the phase II study will be swal-
lowing function, measured using the 19-item composite
MDADI score at 12 months post-treatment. The primary
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outcome of the planned phase III study will be overall sur-
vival (OS).
Secondary outcome measures
These will include data from: (1) functional outcomes
panel (Table 3); (2) acute and late toxicity using CTCAE
version 4.03; (3) QOL using EORTC QLQ C30 and H35
questionnaires; (4) overall survival (OS); (5) disease free
survival (DFS); (6) locoregional control (LC); (7) distant
metastases
Sample size calculation
Phase II
Data show that a 10-point difference in mean MDADI
score can differentiate aspirators from non-aspirators,
tube-dependent from oral eaters and clinically distinct
diet levels [30]. For the study to have 80 % power to de-
tect this difference (two sided 5 % alpha), a sample size
of 148 patients is required (i.e n = 74 in both randomisa-
tions). Given a 20 % loss to follow up as shown in previ-
ous studies, 186 patients will need to be randomised
[20]. Assuming that 15 % of patients recruited are not
randomised post-operatively (10 % who do not require
adjuvant treatment and 5 % who decline randomisation)
and that 10 % who are consented to the study will not
be HPV positive at central HPV testing, we estimate that
242 patients will need to be enrolled into the phase II
study.
Phase III
If the trial proceeds to phase III, then a sample size cal-
culation for non-inferiority will be made. It is likely that
around 800 patients will need to be recruited to prove that
survival is maintained with de-intensified adjuvant therapy
and European collaboration (through the EORTC) will be
required for this.
Statistical analyses
Mean MDADI scores at 12 months will be compared be-
tween arms using either a t-test or nonparametric
methods depending upon distributions. We will adjust
for the randomisation stratification variables using re-
gression techniques. This primary analysis will be con-
ducted when the last patient has had their 12 month
assessment. An Independent Data Monitoring Commit-
tee will review the accumulating data (survival, toxicities,
recruitment) at 6 monthly intervals. Strict monitoring
has been built in for recurrence. A formal interim ana-
lysis will be performed after 38 patients have been ran-
domised in each randomisation (19 per arm), treated
and followed up for 6 months. Within each randomisa-
tion, a stopping rule will be based on observing an abso-
lute observed difference of 6 or more locoregional
recurrences and/or deaths in either of the intervention
arms. For swallowing endpoints, subgroup analysis by
T stage and tumour subsite (tonsil, soft palate, tongue
base) will be carried out, as the most likely relevant
clinical co-variables affecting swallowing function.
Quality Assurance (QA)
All surgeons will need to demonstrate evidence of suit-
able training in the procedures employed and/or an
established surgical practice in the relevant techniques
(TLM/TORS). They should have undertaken a minimum
Table 3 Functional outcomes panel for multidimensional assessment of swallowing function
Study Description Domain Endpoint
MDADI MDADI is a patient reported swallowing outcome
measure, specifically designed and psychometrically
validated for the head and neck cancer population
Swallowing-related QOL Total/Composite, Global, Subscale Scores
(continuous scores: 20 to 100)
WST 100mls WST is a timed swallowing test. Swallow performance Swallow capacity (mls per swallow)
Swallow volume (mls per swallow)
VF VF is the gold standard radiographic measure of
swallowing function. It allows quantification of more
objective endpoints of swallowing function including
pathophysiology, swallowing efficiency and airway
protection.
Swallow physiology MBSImpairment profile (MBSImp)
(continuous scores: oral impairment 0 to
22; pharyngeal impairment 0 to 29) [33]
Airway protection Penetration-aspiration scale (PAS) (ordinal
score: 1 to 8)
Aspiration, yes/no (binary) [34]
Pharyngeal dysphagia
grade
Videofluoroscopic Swallow Grade-Head &
Neck (VSG-HN) (ordinal grade: 0 to 4)
PSS-HN PSS-HN is a 3-item scale designed to evaluate
functional performance of head and neck cancer
patients according to normalcy of diet, eating in
public and understandability of speech
Functional performance
status
Normalcy of diet subscale, public eating
subscale, understandability of speech
scores (ordinal: 0 to 100)
EORTC QLQ C30 H&N35 QOL questionnaires Health related QOL Raw scores from scales and single item
measures are transformed to a
standardised 0–100 final scale score.
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of 5 previous transoral resections for OPSCC. It is
expected that over the duration of the trial, positive
marginal biopsy rates for an individual surgeon will not
exceed 10 %.
The Radiotherapy Quality Assurance (RTQA) programme
for the trial will be coordinated by the National Radiother-
apy Trials Quality Assurance group. A comprehensive
RTQA guidance document has been developed to accom-
pany the main trial protocol. In brief, this will consist of
pre-accrual and on-trial components. Each site must per-
form a pre-accrual outlining benchmark case on one latera-
lised and one non-lateralised case. Sites may need to
complete a pre-accrual planning exercise of a benchmark
case, depending on participation in other national head and
neck trials. Real time review of the first lateralised and non-
lateralised patients recruited by each centre will be carried
out before treatment starts, both for outlining and planning.
All swallow assessments will be conducted by speech
and language therapists with the required level of com-
petency, or appropriately trained research nurses. DVDs
of the VFs will be assessed centrally by members of the
research team to QA the functional endpoint data.
Translational research
The trial is associated with a CR-UK funded bioresource
collection – PATHOS-T. Accordingly, up to five geo-
graphically distinct biopsies from the primary tumour
will be harvested prior to surgical resection. In addition,
up to two samples of involved cervical lymph node tis-
sue will also be collected. Blood samples for research
will also be taken before treatment and at 6 weeks, 6, 12,
18 and 24 months post treatment. Trial participants will
be asked for additional optional consent to participate in
this aspect of the study.
Regulatory approval, sponsorship and current status
PATHOS has ethical approval from the Wales Research
Ethics Committee which is legally recognised by the UK
Ethics Committee Authority for review and approval. It
also has approval from the Medicines and Health Care
Product Regulatory Agency to be conducted in the UK.
The Wales Cancer Trials Unit, a CRUK core funded and
UK Clinical Research Collaboration accredited Clinical
Trials Unit, is coordinating the trial. Velindre NHS Trust
is the sponsor for the trial. A Trial Steering Committee
and an Independent Data Monitoring Committee has
been set up to monitor the progress and safety of the
study. The PATHOS Trial Management Group, includ-
ing clinicians, clinical trial unit staff, patient representa-
tives, nursing and pharmacy representatives carry out
the day-to-day running of the trial. PATHOS is regis-
tered with ClinicalTrials.gov identifier: NCT02215265.
Discussion
A systematic review and meta-analysis of more than 500
OPSCC patients treated with TORS in 17 retrospective
studies concluded that minimally invasive surgical
techniques had a positive effect on QOL and long-term
function as well as good oncological control [31]. The
authors suggested that there was potential to reduce
the intensity of treatment based on successful surgical
control of disease in good prognosis HPV-positive
patients. However, further validation through RCTs, like
PATHOS, is needed prior to widespread shifts in prac-
tice. The RT dose of 50Gy in 25 fractions in the test arm
(B2) of PATHOS was recommended by the National
Cancer Institute Head and Neck Cancer Steering
Committee Clinical Trials Planning Meeting on trans-
oral resection of pharyngeal cancer [32]. This reduced
dose is also currently being used in a parallel US study
(ECOG 3311) for transorally resected HPV-positive
OPSCC. Another ongoing US study (ADEPT) is investi-
gating if concurrent chemotherapy can be withheld in
patients with ECS in the adjuvant setting. PATHOS is
the only study to investigate both the effects of lowering
RT dose and omitting chemotherapy in the same study.
PATHOS will allow clinical and pathological corre-
lations of outcomes for HPV-positive disease, such
that predictive factors for disease behaviour can be
determined specifically in the context of HPV-positive
disease. The study also provides a unique opportunity
in the UK to standardise transoral surgical approaches
for the treatment of OPSCC. It is imperative that in
light of the increased uptake of these new techniques
that surgical QA be established. This will ensure the
rigorous application of appropriate and consistent sur-
gical standards to allow valid comparison whenever
these techniques are used in surgical trials and more
importantly whenever they are used to treat patients.
A panel of objective and self-reported swallowing
assessments has been developed for PATHOS to allow
multidimensional assessment of swallowing function.
This panel will be prospectively validated in the trial
and represents a step change in the standardisation of
swallowing assessment in head and neck trials.
Equally important is the fact that PATHOS will be
the first UK study of post-operative IMRT for head
and neck cancer. A novel aspect of the study will be
outlining of the swallowing structures by investigators
in participating centres. Dose/volume data for swal-
lowing structures will be correlated with long-term
swallowing function, collected prospectively in this
multicentre randomised trial.
PATHOS phase II will open to recruitment in the UK
in June 2015, with a planned recruitment period of
3 years. If the phase II study is successful, we plan to
proceed to a phase III study to establish survival non-
Owadally et al. BMC Cancer  (2015) 15:602 Page 8 of 10
inferiority in the de-intensified treatment arms, which
will require European collaboration.
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